logo
UAE: Food dyes may cause anxiety, hyperactivity, mood swings among kids, warn doctors

UAE: Food dyes may cause anxiety, hyperactivity, mood swings among kids, warn doctors

Khaleej Times28-04-2025
Doctors in the UAE are warning that food dyes can cause hyperactivity, mood swings and irritability in some children and teenagers.
The concern has once again gained attention following the recent announcement by the US Department of Health and Human Services and the US Food and Drug Administration (FDA) about new plans to phase out all petroleum-based synthetic dyes from food supply.
Research indicates that food dyes can contribute to hyperactivity and mood issues among young people. If consumed regularly, dyed foods could also make children feel more anxious and high-strung.
Dr Fatma Mohamed Mahmoud Ibrahim, specialist pediatrics, Burjeel Medical Centre, Al Shamkha, said, 'Studies like the Southampton study and reviews by the European Food Safety Authority (EFSA) found that some food dyes, especially when combined with preservatives, may worsen these behaviors. Recently, the FDA has started to review these findings more seriously.
"In the UAE, we are seeing similar patterns as children's diets have more processed foods and snacks containing these dyes. A study by UAE University has also raised concerns about this, although, we still need more research to understand the full long-term impact on our local population.'
Synthetic dyes common in children's products
Medics explained synthetic food dyes are very common in the UAE, especially in products aimed at kids, 'like candies, colorful cereals, juices, and bakery items. Many products still use dyes like Tartrazine (E102), Sunset Yellow (E110), and Allura Red (E129),' added Ibrahim.
Notably, in a social media post earlier this year, the Ministry of Climate Change and Environment UAE (MOCCEUAE) emphasised ongoing updates to technical standards to protect consumer health. They stated that UAE regulations set safe limits for colourant additives based on risk assessments and global standards.
Imported foods also undergo strict inspections and testing with local authorities to ensure safety.
Worsening food consumption patterns
Dr Mamata Bothra, specialist pediatrics and neonatologist, International Modern Hospital Dubai, said, 'Food dyes can definitely worsen signs of hyperactivity and also make some children more agitated.'
Healthcare experts highlighted studies have shown associations between exposure to synthetic food dyes and the exacerbation of symptoms of Attention Deficit/Hyperactivity Disorder (ADHD).
'I have seen a rise in these cases in recent years and exposure to food dyes in the early years is also seen to be causing a rise in these symptoms. Children consuming percentage of food with artificial dyes is three to four times more than seen in late 90s and early years of 2000. These effects can have long time implication in terms of behaviour. Lots of mood swings, agitations, increase in anxiety, decreased focus and sleep disorders are seen in children consuming high percentage of these food stuff.
"Overall, everywhere the use of synthetic dyes has increased. The availability of packed foods, consumption of aerated coloured drinks, fast foods, candies etc are all on a rise,' added Bothra.
Dr Fatma Mohamed Mahmoud Ibrahim, specialist pediatrics, Burjeel Medical Centre, Al Shamkha, said, 'While specific UAE-wide data on this topic is still emerging, the high availability of processed foods in our markets makes this concern highly relevant.'
However, doctors pointed out most of the time, the effects are short-term. Symptoms like restlessness, mood swings, and poor concentration often happen within a few hours after eating foods with dyes. However, if children keep eating these foods regularly, it could add up over time and affect their long-term behavior and learning issues.
'Parents play a crucial role…they should carefully check food labels, opt for natural color alternatives, and reduce the overall consumption of highly processed foods. Creating a healthier, dye-free diet can significantly improve a child's behavior, learning ability, and overall wellbeing,' added Ibrahim.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

FDA recommends restricting 7-OH opioid products found in some vapes
FDA recommends restricting 7-OH opioid products found in some vapes

Al Etihad

time2 days ago

  • Al Etihad

FDA recommends restricting 7-OH opioid products found in some vapes

29 July 2025 19:44 ABU DHABI (ALETIHAD)The US Food and Drug Administration has recommended a scheduling action to control certain 7-hydroxymitragynine (also known as 7-OH1) products that are commonly found in vapes. The FDA is specifically targeting 7-OH, a concentrated byproduct of the kratom plant that is increasingly recognised as having potential for abuse because of its ability to bind to opioid receptors. 'Today, we're taking action on 7-OH as a critical step in the fight against opioid addiction,' said HHS Secretary Robert F. Kennedy, Jr.'We will protect the health of our nation's youth as we advance our mission to Make America Healthy Again.'This recommendation follows a thorough medical and scientific analysis by the FDA, and is one of several efforts to address the agency's concerns around the growing availability and use of 7-OH opioid products. There are no FDA-approved 7-OH drugs, 7-OH is not lawful in dietary supplements and 7-OH cannot be lawfully added to conventional foods. 'Vape stores are popping up in every neighborhood in America, and many are selling addictive products like concentrated 7-OH. After the last wave of the opioid epidemic, we cannot get caught flat-footed again,' said FDA Commissioner Marty Makary, M.D., M.P.H.'7-OH is an opioid that can be more potent than morphine. We need regulation and public education to prevent another wave of the opioid epidemic.'The FDA is particularly concerned with the growing market of 7-OH products that may be especially appealing to children and teenagers, such as fruit-flavored gummies and ice cream cones. These products may not be clearly or accurately labeled as to their 7-OH content and are sometimes disguised or marketed as kratom. The FDA has issued a letter to health care professionals, and has warned consumers about the risks associated with 7-OH products. Source: Aletihad - Abu Dhabi

Novo Nordisk faces 'show me' moment to boost Wegovy growth after US copycat ban
Novo Nordisk faces 'show me' moment to boost Wegovy growth after US copycat ban

Al Etihad

time3 days ago

  • Al Etihad

Novo Nordisk faces 'show me' moment to boost Wegovy growth after US copycat ban

28 July 2025 14:38 LONDON (REUTERS)A US ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will need to show more robust growth in the months ahead to bolster market confidence, investors and analysts Wegovy prescriptions have increased by about 33% since May 22, when a US Food and Drug Administration ban on so-called compounded versions of Wegovy took effect, amounting to 181,200 in the week ended July 18, according to data from IQVIA that was shared with Reuters by industry Wegovy prescriptions have also increased, narrowing the lead for Eli Lilly and Co's Zepbound. In the week ended May 23, U.S. Zepbound prescriptions exceeded Wegovy by nearly 175,000. By July 18, the gap was about 133, signs of a shift come at a critical juncture for Novo. After Wegovy's initial stunning success, investor confidence was rattled when Zepbound and compounders started to slow the drug's then in May, the Danish company cut its full-year sales and earnings forecasts and announced the surprise exit of Chief Executive Lars Fruergaard Jorgensen, citing market challenges and a stock price nearly 60% below its 2024 said at the time he expected the FDA compounding ban to lift sales in the second half of this year. Investors are keen to hear whether that is still likely when the company reports quarterly earnings on August leaves the drugmaker in what Barclays analyst Emily Field called a "show me" phase - no longer buoyed by optimism about a turnaround but under pressure to sales of Wegovy catapulted Novo to become Europe's most valuable listed company, peaking in June 2024 at about 615 billion euros, after the weekly injection became the first highly-effective obesity treatment approved in the US in supply disruptions and gaps in health insurance coverage for Wegovy helped fuel the market for cheaper compounded - or copycat - versions, which are allowed under US law when drugs are in sentiment on Novo soured after the company lost ground to US rival Eli Lilly, which launched Zepbound in late its first full-year forecast downgrade since Wegovy's launch, Novo said in May it expected local-currency sales growth of 13-21%, down from a previous forecast of 16-24%. Operating profit growth is projected at 16-24%, versus 19-27% more of the patients who had turned to compounded drugs is key to meeting those targets. The FDA determined that Wegovy was no longer in shortage in February, leading to the ban on compounded versions. Novo has rolled out new tactics to bring patients back, including a limited-time discount for one month's supply, and secured better coverage from insurer CVS Health.

FDA to appoint George Tidmarsh as top drug regulator
FDA to appoint George Tidmarsh as top drug regulator

Zawya

time21-07-2025

  • Zawya

FDA to appoint George Tidmarsh as top drug regulator

U.S. Food and Drug Administration commissioner Marty Makary has chosen former biotech executive George Tidmarsh as the director of the Center for Drug Evaluation and Research, Bloomberg News reported on Monday, citing a person familiar with the decision. Tidmarsh's appointment as the agency's top drug regulator could be announced as soon as Monday, the report said, citing the person who asked not to be identified. Jacqueline Corrigan-Curay, the acting head of the division, recently announced she was leaving the agency, according to the report. The Department of Health and Human Services, which oversees the FDA, did not immediately respond to a Reuters request for comment. Tidmarsh also did not immediately respond to email and LinkedIn requests for comment. Tidmarsh, a Stanford University-affiliated pediatrician, will oversee one of the FDA's largest and most important divisions, which regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. In May, he took part in an FDA expert panel to discuss the safety and necessity of talc as an additive in food, drug and cosmetic products. "It's not if talc should be removed from the U.S. market. It's a matter of how and when. It's a dangerous substance. We have safer, more modern low cost alternatives," Tidmarsh had then said. He previously served as the chief executive officer of Horizon Pharma — a company he founded in 2005. While at Horizon, he led all aspects of development of Duexis, which was approved by the FDA for the treatment of rheumatoid arthritis. Tidmarsh also held senior positions at other biotechs such as SEQUUS Pharmaceuticals and Coulter Pharmaceutical. He retired from Revelation Biosciences' board in May. (Reporting by Sriparna Roy and Sneha S K in Bengaluru; Editing by Shilpi Majumdar)

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store